Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
20,324 results
- Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer…
- Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01938716).
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01360593).
- Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459614).
- GEMINIIndependent statistical analysis of A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GEMINI IIIndependent statistical analysis of Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GEMINI LTSIndependent statistical analysis of An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GEMINI Study – A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: Complete Statistical AnalysisIndependent statistical analysis of GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GEMMIndependent statistical analysis of A Risky Sex Prevention Intervention for Middle School Age Minority Girls: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GEMNICIndependent statistical analysis of Gemfibrozil for Nicotine Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02638597).
- Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm: Complete Statistical AnalysisIndependent statistical analysis of Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemzar, Cisp, Sunitinib Urothelial Ca: Complete Statistical AnalysisIndependent statistical analysis of Gemzar, Cisp, Sunitinib Urothelial Ca: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00821327).
- GEN206Independent statistical analysis of Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00677924).
- Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT): Complete Statistical AnalysisIndependent statistical analysis of Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gene Signatures of Influenza Vaccine Responses in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Gene Signatures of Influenza Vaccine Responses in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03603509).
- Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) – Retinitis Pigmentosa GTPase Regulator (RPGR): Complete Statistical AnalysisIndependent statistical analysis of Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1: Complete Statistical AnalysisIndependent statistical analysis of Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02122952).
- Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD: Complete Statistical AnalysisIndependent statistical analysis of Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GENEr8-2Independent statistical analysis of Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg: primary endpoint results, effect estimate with confidence…
- GENEr8-AAV5+Independent statistical analysis of Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GENERATIONIndependent statistical analysis of Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3: Complete Statistical AnalysisIndependent statistical analysis of Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00878969).
- Genetic and Biochemical Markers of Interferon-Induced Depression.: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Biochemical Markers of Interferon-Induced Depression.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00252538).
- Genetic and Brain Mechanisms of Naltrexone’s Treatment Efficacy for Alcoholism: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920829).
- Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetic and Neural Factors in Alcohol-Related Cognition: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Neural Factors in Alcohol-Related Cognition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03725345).
- Genetic Basis for Variation in the Renal Elimination of Metformin: Complete Statistical AnalysisIndependent statistical analysis of Genetic Basis for Variation in the Renal Elimination of Metformin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00187720).
- Genetic Effects on Dopamine Response to an Opiate: Complete Statistical AnalysisIndependent statistical analysis of Genetic Effects on Dopamine Response to an Opiate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01878006).
- Genetic Predictors of Benefit to Pembrolizumab: Complete Statistical AnalysisIndependent statistical analysis of Genetic Predictors of Benefit to Pembrolizumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02710396).
- Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes: Complete Statistical AnalysisIndependent statistical analysis of Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00108303).
- Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population: Complete Statistical AnalysisIndependent statistical analysis of Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA): Complete Statistical AnalysisIndependent statistical analysis of Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03362957).
- GeniProIndependent statistical analysis of Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: Complete Statistical AnalysisIndependent statistical analysis of Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing: Complete Statistical AnalysisIndependent statistical analysis of Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02930824).
- Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: Complete Statistical AnalysisIndependent statistical analysis of Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GeoScan and Remote Geo Smoking Study: Neural and Behavioral Correlates of Smokers’ Exposure to Retail Environments: Complete Statistical AnalysisIndependent statistical analysis of GeoScan and Remote Geo Smoking Study: Neural and Behavioral Correlates of Smokers' Exposure to Retail Environments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- GER Poses a Potential Risk for Late Complications of BPD: Complete Statistical AnalysisIndependent statistical analysis of GER Poses a Potential Risk for Late Complications of BPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03014453).
- Geriatric Ketamine for Pain Management Study: Complete Statistical AnalysisIndependent statistical analysis of Geriatric Ketamine for Pain Management Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02673372).